Why did ABVX Surge Over 400% in Premarket Trading?

French biotechnology company Abivax SA (NASDAQ: ABVX) experienced an extraordinary surge in premarket trading on July 23, 2025, with shares skyrocketing over 400% following the announcement of positive Phase 3 clinical trial results for its ulcerative colitis treatment.

The company reported compelling results from its ABTECT trials, which evaluated obefazimod, a first-in-class oral miR-124 enhancer, in patients with moderate to severely active ulcerative colitis.

This breakthrough announcement represents a significant milestone for the clinical-stage biotechnology company and offers new hope for patients suffering from this chronic inflammatory bowel disease.

Little-Known French Biotech Firm’s US-Listed Shares Skyrocket in Premarket

ABVX shares opened the premarket session at $49.88, representing a staggering 398.80% increase from the previous close of $10.00. The dramatic surge was triggered by the company’s announcement of successful Phase 3 trial results released after market hours on July 22, 2025. Trading volume spiked significantly as investors reacted to the breakthrough clinical data.

The company’s market capitalization jumped to approximately $665 million following the premarket surge, reflecting investor confidence in the commercial potential of obefazimod. With a 52-week range of $4.77 to $13.17 prior to the announcement, the premarket price of nearly $50 represents an extraordinary breakout from previous trading patterns. The stock had been trading with high volatility, as evidenced by its beta of 1.53, making it particularly sensitive to clinical development news.

Key financial metrics show the company had preliminary cash and cash equivalents of approximately $71.4 million as of June 30, 2025, providing runway for continued operations and regulatory submissions. The company has postponed its H1 2025 financial results from August 11 to September 8, 2025, likely to focus management attention on the significant clinical milestone.

Join our Telegram group and never miss a breaking digital asset story.

Breakthrough Clinical Results Drive Investor Enthusiasm for ABVX

The dramatic stock surge was driven by Abivax’s announcement of positive topline results from both ABTECT-1 and ABTECT-2 Phase 3 trials, which collectively enrolled 1,275 patients across over 600 clinical sites in 36 countries.

The 50mg once-daily dose of obefazimod demonstrated a compelling pooled 16.4% placebo-adjusted clinical remission rate at Week 8, meeting the FDA primary endpoint with high statistical significance (p<0.0001). Individually, ABTECT-1 showed a 19.3% placebo-adjusted remission rate while ABTECT-2 achieved 13.4%.

The trials included a well-balanced population with 47.3% of participants having inadequate response to prior advanced therapies, including the largest population of patients with inadequate response to JAK inhibitor therapy in Phase 3 ulcerative colitis trials to date. This represents a significant addressable market opportunity, as these patients have limited treatment options. The drug also demonstrated favorable tolerability with no new safety signals observed, maintaining consistency with earlier clinical experience.

Looking ahead, 678 patients who achieved clinical response have enrolled in the ongoing maintenance trial (ABX464-107), with topline results expected in Q2 2026. Contingent on positive maintenance results, Abivax plans to submit New Drug Applications to both the FDA and European Medicines Agency in the second half of 2026, positioning obefazimod as a potential first-in-class treatment option for ulcerative colitis patients.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.